Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma

Inclusion Criteria:

* Histologically verified adenocarcinoma arisen from gallbladder, extra or intrahepatic bile ducts or malignant cells consistent with the above and concomitant radiologic findings consistent with cholangiocarcinoma.
* Curative treatment presently discounted (surgery, stereotactic radiotherapy, etc.)
* KRAS analyzed and found wild-type (wt) or mutated
* PS 0-2
* Evaluable disease according to RECIST criteria, i.e., the disease does not need to be measurable
* Haematology:

  * ANC ≥ 1.5 x 10\^9/l
  * Thrombocytes ≥ 100x10\^9/l
* Biochemistry:

  * Bilirubinaemia ≤ 3 x upper normal value
  * ALAT ≤ 5 x upper normal value
* Creatinin ≤ upper normal value. If raised creatinin, the measured or calculated GFR must be at least 50% of the lower normal value.
* Fertile women must present a negative pregnancy test and use birth control during and 3 months after treatment. The following methods are considered safe birth control: Birth control pills, coil, gestagen deposit injection, subdermal implantation, hormonal vagina ring, and transdermal deposit band-aid)
* Oral and written informed consent

Exclusion Criteria:

* Chemotherapy within 4 weeks
* Radiotherapy within 4 weeks
* Immunotherapy within 4 weeks
* Other concomitant experimental treatment
* Known neuropathy ≥ grade 2
* Serious congruous medical disease
* Other previous malignant disease within 5 years, excl. non-melanoma skin cancer and carcinoma in situ cervicis uteri
* Previous serious and unexpected reactions to fluoropyrimidine treatment
* Hypersensitivity to one or more of the active substances, auxiliary substances or fluoruracil
* Patients with interstitial pneumonitis or pulmonary fibrosis